Patents by Inventor John F. R. Robertson
John F. R. Robertson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210318320Abstract: The invention generally relates to the field of immunoassays. In particular, the invention relates to use of a calibrator material to calibrate immunoassays for autoantibodies.Type: ApplicationFiled: November 19, 2020Publication date: October 14, 2021Inventors: John F. R. Robertson, Andrea Murray, Caroline Chapman, Anthony Barnes
-
Patent number: 9696319Abstract: A method of determining the immune response of a mammal to circulating tumor marker proteins is described in which a sample of bodily fluid, for example plasma or serum, is contacted with a panel of two or more distinct tumor marker antigen. The presence of complexes between the tumor marker antigens and any autoantibodies to the antigens present in the sample are detected and provide an indication of an immune response to a circulating tumor marker protein. The method is useful for the diagnosis of cancer, particularly for identifying new or recurrent cancer in an otherwise assymptomatic patient.Type: GrantFiled: January 12, 2012Date of Patent: July 4, 2017Assignee: Oncimmune Ltd.Inventors: John F. R. Robertson, Catherine R. L. Graves, Michael R. Price, Frances M Price
-
Publication number: 20170074884Abstract: The invention generally relates to the field of immunoassays. In particular, the invention relates to use of a calibrator material to calibrate immunoassays for autoantibodies.Type: ApplicationFiled: September 23, 2016Publication date: March 16, 2017Inventors: John F.R. ROBERTSON, Andrea MURRAY, Caroline Chapman, Anthony BARNES
-
Patent number: 8927223Abstract: The application generally relates to the field of diagnostic or prognostic assays and in particular relates to assays for the detection of antibodies in a sample comprising patient bodily fluid, wherein such antibodies are used as biological markers of a disease state or disease susceptibility. The assay is based on cross-titration of both the patient bodily fluid to be tested for the antibody and an antigen used to detect the antibody by specific binding.Type: GrantFiled: September 24, 2013Date of Patent: January 6, 2015Assignee: OncImmune Ltd.Inventors: John F. R. Robertson, Andrea Murray, Caroline Chapman, Anthony Barnes
-
Publication number: 20140038212Abstract: The application generally relates to the field of diagnostic or prognostic assays and in particular relates to assays for the detection of antibodies in a sample comprising patient bodily fluid, wherein such antibodies are used as biological markers of a disease state or disease susceptibility. The assay is based on cross-titration of both the patient bodily fluid to be tested for the antibody and an antigen used to detect the antibody by specific binding.Type: ApplicationFiled: September 24, 2013Publication date: February 6, 2014Applicant: OncImmune Ltd.Inventors: John F.R. Robertson, Andrea Murray, Caroline Chapman, Anthony Barnes
-
Patent number: 8574848Abstract: The invention generally relates to the field of diagnostic or prognostic assays and in particular relates to assays for the detection of antibodies in a sample comprising patient bodily fluid, wherein such antibodies are used as biological markers of a disease state or disease susceptibility. The assay is based on cross-titration of both the patient bodily fluid to be tested for the antibody and an antigen used to detect the antibody by specific binding.Type: GrantFiled: September 12, 2007Date of Patent: November 5, 2013Assignee: OncImmune Ltd.Inventors: John F. R. Robertson, Andrea Murray, Caroline Chapman, Anthony Barnes
-
Publication number: 20130090251Abstract: A method of determining the immune response of a mammal to circulating tumour marker proteins is described in which a sample of bodily fluid, for example plasma or serum, is contacted with a panel of two or more distinct tumour marker antigen. The presence of complexes between the tumour marker antigens and any autoantibodies to the antigens present in the sample are detected and provide an indication of an immune response to a circulating tumour marker protein. The method is useful for the diagnosis of cancer, particularly for identifying new or recurrent cancer in an otherwise assymptomatic patient.Type: ApplicationFiled: April 3, 2012Publication date: April 11, 2013Applicant: Onclmmune LimitedInventors: John F.R. Robertson, Catherine R.L. Graves, Frances M. Price
-
Publication number: 20120115749Abstract: A method of determining the immune response of a mammal to circulating tumour marker proteins is described in which a sample of bodily fluid, for example plasma or serum, is contacted with a panel of two or more distinct tumour marker antigen. The presence of complexes between the tumour marker antigens and any autoantibodies to the antigens present in the sample are detected and provide an indication of an immune response to a circulating tumour marker protein. The method is useful for the diagnosis of cancer, particularly for identifying new or recurrent cancer in an otherwise assymptomatic patient.Type: ApplicationFiled: January 12, 2012Publication date: May 10, 2012Applicant: Onclmmune LimitedInventors: John F.R. Robertson, Catherine R.L. Graves, Michael R. Price, Frances Margaret Price
-
Patent number: 8114604Abstract: A method of determining the immune response of a mammal to circulating tumour marker proteins is described in which a sample of bodily fluid, for example plasma or serum, is contacted with a panel of two or more distinct tumour marker antigen. The presence of complexes between the tumour marker antigens and any autoantibodies to the antigens present in the sample are detected and provide an indication of an immune response to a circulating tumour marker protein. The method is useful for the diagnosis of cancer, particularly for identifying new or recurrent cancer in an otherwise assymptomatic patient.Type: GrantFiled: December 10, 2007Date of Patent: February 14, 2012Assignee: OncImmune Ltd.Inventors: John F. R. Robertson, Catherine R. L. Graves, Michael R. Price, Frances Margaret Price, legal representative
-
Publication number: 20090176319Abstract: The invention generally relates to the field of immunoassays. In particular, the invention relates to use of a calibrator material to calibrate immunoassays for autoantibodies.Type: ApplicationFiled: December 23, 2008Publication date: July 9, 2009Applicant: Onclmmune LimitedInventors: John F. R. Robertson, Andrea Murray, Caroline Chapman, Anthony Barnes
-
Publication number: 20080213921Abstract: The invention generally relates to the field of diagnostic or prognostic assays and in particular relates to assays for the detection of antibodies in a sample comprising patient bodily fluid, wherein such antibodies are used as biological markers of a disease state or disease susceptibility. The assay is based on cross-titration of both the patient bodily fluid to be tested for the antibody and an antigen used to detect the antibody by specific binding.Type: ApplicationFiled: September 12, 2007Publication date: September 4, 2008Inventors: John F.R. Robertson, Andrea Murray, Caroline Chapman, Anthony Barnes
-
Patent number: 7402403Abstract: A method of determining the immune response of a mammal to circulating tumour marker proteins is described in which a sample of bodily fluid, for example plasma or serum, is contacted with a panel of two or more distinct tumour marker antigens. The presence of complexes between the tumour marker antigens and any autoantibodies to the antigens present in the sample are detected and provide an indication of an immune response to a circulating tumour marker protein. The method is useful for the diagnosis of cancer, particularly for identifying new or recurrent cancer in an otherwise assymptomatic patient.Type: GrantFiled: May 11, 1999Date of Patent: July 22, 2008Assignee: OncImmune LimitedInventors: John F. R. Robertson, Catherine R. L. Graves, Frances M. Price, legal representative, Michael R. Price
-
Publication number: 20080153113Abstract: A method of determining the immune response of a mammal to circulating tumour marker proteins is described in which a sample of bodily fluid, for example plasma or serum, is contacted with a panel of two or more distinct tumour marker antigen. The presence of complexes between the tumour marker antigens and any autoantibodies to the antigens present in the sample are detected and provide an indication of an immune response to a circulating tumour marker protein. The method is useful for the diagnosis of cancer, particularly for identifying new or recurrent cancer in an otherwise assymptomatic patient.Type: ApplicationFiled: December 10, 2007Publication date: June 26, 2008Inventors: John F.R. Robertson, Catherine R.L. Graves, Michael R. Price, Frances M. Price